Prognostic effect of systemic inflammation in patients undergoing cytoreductive surgery and hyperthermic intrathoracic chemotherapy
Turkish Journal of Thoracic and Cardiovascular Surgery, vol.34, no.2, pp.192-197, 2026 (SCI-Expanded, Scopus)
- Publication Type: Article / Article
- Volume: 34 Issue: 2
- Publication Date: 2026
- Doi Number: 10.4274/tjtcs.2025.28900
- Journal Name: Turkish Journal of Thoracic and Cardiovascular Surgery
- Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Page Numbers: pp.192-197
- Keywords: cytoreductive surgery, HITHOC, pleural mesothelioma, prognosis, Systemic inflammation
- Open Archive Collection: AVESIS Open Access Collection
- Acibadem Mehmet Ali Aydinlar University Affiliated: No
Abstract
Background: To investigate prognostic significance of systemic inflammation-related parameters in patients undergoing cytoreductive surgery and hyperthermic intrathoracic chemotherapy for malignant pleural mesothelioma (MPM). Methods: Data from 55 patients were analyzed retrospectively. Demographic characteristics, survival outcomes and inflammation-related parameters (neutrophil/lymphocyte ratio [NLR], platelet/lymphocyte ratio [PLR], lymphocyte/monocyte ratio [LMR] and pan-immune inflammation value [PIV]) were evaluated. Results: Overall survival (OS) was 61.26±13.03 (3-79) months in patients with low NLR, whereas, it was 23.18±3.53 (1-147) months in patients with high NLR (p=0.012). No statistically significant differences in OS were detected according to LMR, PLR and PIV. In addition, OS was 24.40±4.91 (3-92) months in men and 52.8±10.92 (1-147) months in women (p=0.031). Conclusion: In this study, NLR was found to be associated with survival in agreement with the existing literature, thereby distinguishing it from other inflammatory markers as a prognostic factor. In clinical practice, predicting patient prognosis based on pre-treatment NLR may provide a valuable guidance for treatment decision-making.